CBD Research: Peer-Reviewed Research Consensus
Overview
The research base for cbd research includes 1137 peer-reviewed studies spanning 1984–2026. Of these, 116 provide strong evidence, including 23 meta-analyses and 160 randomized controlled trials. Key findings with strong support include: meta-analysis of 11 rcts finding selective cannabinoids provide a small but significant reduction in neuropathic pain (-0, and meta-analysis of 550 patients found cbd reduced seizures by ~20 percentage points in severe childhood epilepsies. However, several findings remain debated, and the evidence is not uniform across all areas. Many studies have methodological limitations including small sample sizes, short follow-up periods, and reliance on self-reported data.
What the Research Shows
Findings supported by multiple peer-reviewed studies. Stronger evidence means more consistency across study types.
Meta-analysis of 11 RCTs finding selective cannabinoids provide a small but significant reduction in neuropathic pain (-0
Strong EvidenceMeta-analysis of 550 patients found CBD reduced seizures by ~20 percentage points in severe childhood epilepsies
Strong EvidenceA Lancet meta-analysis of 83 studies found scarce evidence that cannabinoids help depression, anxiety, PTSD, or other mental disorders, with THC products doubling adverse event rates versus placebo
Strong EvidenceWhere Scientists Disagree
Areas where research shows conflicting results or ongoing scientific debate.
CBD at approximately 700 mg/day for six weeks showed no significant benefit for Huntington's Disease symptoms in 15 patients, but was well tolerated with no toxicity
Moderate EvidenceA review by THC discoverer Raphael Mechoulam tracing cannabinoids from ancient use to modern clinical applications in nausea, appetite, multiple sclerosis, arthritis, and neuroprotection
Moderate EvidenceRandomized trial in 16 MS patients found neither oral THC nor cannabis extract reduced spasticity, and both worsened patients' overall impression compared to placebo
Moderate EvidenceGW Pharmaceuticals developed Sativex and other cannabis medicines, with phase III trials showing significant neuropathic pain reduction in MS, leading to licensing with Bayer AG
Moderate EvidenceWhat We Still Don't Know
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Evidence Breakdown
Distribution of study types in this research area. Higher-tier evidence (meta-analyses, RCTs) provides stronger conclusions.
Key Studies
The most impactful research in this area.
Cannabis Use Makes Quitting Tobacco Harder, But CBD Might Help
With 18-22% of tobacco users also using cannabis, understanding how co-use affects quit attempts is critical. The key distinction here is that casual cannabis use hurts cessation, but pharmacologically targeted CBD could actually help.
Nearly 29% of North Americans have tried CBD, about double the rate in Europe
Despite the explosive growth of the CBD market, no prior systematic assessment of how many people actually use CBD existed. These numbers provide a baseline for tracking trends as regulations and products evolve.
Meta-Analysis Found CBD and THC Had Trivial Effects on Blood Inflammation Markers
CBD and THC are widely marketed as anti-inflammatory, often based on preclinical data. This meta-analysis of actual human clinical trials shows that the anti-inflammatory effects observed in cells and animals have not consistently translated to measurable changes in human blood markers.
Major meta-analysis of 152 RCTs finds cannabinoid effectiveness varies dramatically by specific drug and condition
By analyzing cannabinoid medications separately rather than lumping them together, this study reveals that the question "does cannabis work?" is misleading. The answer depends entirely on which cannabinoid and which condition.
Meta-analysis confirmed CBD reduces seizures by 33% in treatment-resistant epilepsy
This meta-analysis provides the strongest quantitative evidence to date supporting CBD as an add-on treatment for three of the most difficult-to-treat pediatric epilepsy syndromes.
CBD reduced seizures in both Dravet and Lennox-Gastaut syndromes, with enhanced effects when combined with clobazam
This meta-analysis directly addresses the critical question of whether CBD's seizure reduction is partly driven by its interaction with clobazam, showing CBD is effective in both clobazam users and the overall population, but more so in the combination.
Research Timeline
How our understanding of this topic has evolved.
Pre-2000
4 studies published. Includes 1 RCTs.
2000–2009
52 studies published. Includes 17 RCTs, 4 strong-evidence studies.
2010–2014
74 studies published. Includes 19 RCTs, 10 strong-evidence studies.
2015–2019
190 studies published. Includes 4 meta-analyses, 23 RCTs, 31 strong-evidence studies.
2020–present
817 studies published. Includes 19 meta-analyses, 100 RCTs, 71 strong-evidence studies.
About This Consensus
This consensus synthesizes 1137 peer-reviewed studies: 23 meta-analyses (2%), 160 randomized controlled trials (14%), 122 observational studies (11%), 334 reviews (29%), 30 case studies (3%), 468 other study types (41%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
This page synthesizes findings from 1,137 peer-reviewed studies. It is not medical advice. Always consult a healthcare provider for personal health decisions.